Ask OpenScientist

Ask a research question about Fibrocartilaginous Embolism. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
7
Phenotypes
4
Pathograph
3
Treatments
1
Deep Research

Pathophysiology

4
Nucleus pulposus fibrocartilage embolization
Acute vertical disc herniation can introduce nucleus pulposus fibrocartilage into spinal vasculature, with retrograde embolization to a central or spinal artery.
intervertebral disk link anterior spinal artery link
Show evidence (2 references)
PMID:14970983 SUPPORT Human Clinical
"It is postulated that an acute vertical disk herniation of the nucleus pulposus material can lead to spinal cord infarction by a retrograde embolization to the central artery."
This review/case report states the proposed nucleus pulposus embolization mechanism.
DOI:10.1177/0883073809355822 SUPPORT Human Clinical
"Fibrocartilaginous embolization is a rare cause of ischemic myelopathy caused by embolization of intersomatic disk nucleus pulposus into spinal vasculature during Valsalva-like maneuvers."
This independently supports nucleus pulposus embolization into spinal vasculature.
Spinal cord infarction
Vascular occlusion by fibrocartilage causes spinal cord ischemia and infarction, which can present as acute myelopathy and may be misdiagnosed as inflammatory transverse myelitis.
neuron link
response to hypoxia link ↑ INCREASED
spinal cord link
Show evidence (2 references)
PMID:26833287 SUPPORT Human Clinical
"Fibrocartilaginous Embolism (FCE) has been reported to represent 5.5% of spinal cord infarctions."
This review identifies FCE as a cause of spinal cord infarction.
PMID:26833287 SUPPORT Human Clinical
"FCE of the spinal cord, often mis-diagnosed as transverse myelitis, may be more common than presumed."
This supports spinal-cord FCE as an acute myelopathy mimic.
Acute ischemic myelopathy
Infarction of the spinal cord causes abrupt motor and sensory dysfunction, often with severe back pain at onset and variable long-term neurological recovery.
spinal cord link
Show evidence (1 reference)
PMID:37873837 SUPPORT Human Clinical
"We present the case of an otherwise healthy 17-year-old student who experienced sudden onset of severe low-back pain amidst intensive physical training, which rapidly deteriorated to complete sensory-motor paralysis of his lower limbs."
This case/review supports sudden pain followed by severe sensory-motor myelopathy.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Fibrocartilaginous Embolism Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

7
Nervous System 2
Lower-limb paralysis Paraplegia (HP:0010550)
Show evidence (1 reference)
PMID:37873837 SUPPORT Human Clinical
"We present the case of an otherwise healthy 17-year-old student who experienced sudden onset of severe low-back pain amidst intensive physical training, which rapidly deteriorated to complete sensory-motor paralysis of his lower limbs."
This supports acute lower-limb sensory-motor paralysis.
Somatic sensory dysfunction Somatic sensory dysfunction (HP:0003474)
Show evidence (1 reference)
PMID:37873837 SUPPORT Human Clinical
"complete sensory-motor paralysis of his lower limbs."
This directly supports sensory dysfunction as part of FCE-associated lower-limb sensory-motor paralysis.
Constitutional 2
Back pain Back pain (HP:0003418)
Temporal: ACUTE
Show evidence (1 reference)
PMID:37873837 SUPPORT Human Clinical
"We present the case of an otherwise healthy 17-year-old student who experienced sudden onset of severe low-back pain amidst intensive physical training, which rapidly deteriorated to complete sensory-motor paralysis of his lower limbs."
This directly supports sudden severe low-back pain at presentation.
Autonomic bladder or bowel dysfunction Urinary incontinence (HP:0000020)
Show evidence (1 reference)
PMID:37456462 PARTIAL Human Clinical
"fecal or urinary incontinence"
This supports autonomic bladder or bowel dysfunction in anterior spinal artery ischemia, a downstream spinal cord infarction pattern relevant to FCE.
Other 3
Spinal cord infarction
Show evidence (1 reference)
PMID:26833287 SUPPORT Human Clinical
"Fibrocartilaginous Embolism (FCE) has been reported to represent 5.5% of spinal cord infarctions."
This supports spinal cord infarction as the core FCE lesion.
Acute myelopathy
Show evidence (1 reference)
PMID:26833287 SUPPORT Human Clinical
"FCE of the spinal cord, often mis-diagnosed as transverse myelitis, may be more common than presumed."
This supports acute myelopathy as the clinical syndrome frequently confused with transverse myelitis.
Paraparesis Paraparesis (HP:0002385)
Show evidence (1 reference)
PMID:14970983 SUPPORT Human Clinical
"We present a previously healthy 16-year-old boy with sudden onset of back pain and progressive paraparesis within 36 hours after lifting exercises in a squat position."
This case/review supports progressive paraparesis after exertion.
💊

Treatments

3
Supportive rehabilitation after ischemic myelopathy
Action: supportive care MAXO:0000950
Treatment is mainly supportive, focused on acute assessment, prevention of complications, and inpatient or outpatient rehabilitation to maximize neurologic and functional recovery.
Show evidence (1 reference)
PMID:37873837 SUPPORT Human Clinical
"He subsequently received inpatient rehabilitation treatment for four months, after which he was followed as an outpatient for a total period of 16 months."
This supports rehabilitation-centered management after suspected FCE ischemic myelopathy.
IV methylprednisolone during initial infarction work-up
Action: Pharmacotherapy NCIT:C15986
Agent: methylprednisolone
IV methylprednisolone has been used during initial evaluation when the differential includes inflammatory myelopathy, but this is case-level management rather than proven disease-specific therapy.
Show evidence (1 reference)
PMID:37873837 PARTIAL Human Clinical
"He was treated with IV Methylprednisolone and anticoagulation after the initial work-up suggested spinal cord infarction."
This supports reported use of IV methylprednisolone during initial suspected spinal cord infarction work-up.
Anticoagulation during initial infarction work-up
Action: Pharmacotherapy NCIT:C15986
Agent: anticoagulant agent
Anticoagulation has been used during initial management of suspected spinal cord infarction in FCE, but evidence remains anecdotal and not disease-specific.
Show evidence (1 reference)
PMID:37873837 PARTIAL Human Clinical
"He was treated with IV Methylprednisolone and anticoagulation after the initial work-up suggested spinal cord infarction."
This supports reported anticoagulation during initial suspected spinal cord infarction work-up.
🌍

Environmental Factors

1
Axial loading or Valsalva-associated spinal pressure
Activities that increase intradiscal pressure, such as axial loading with a Valsalva maneuver or lifting exercises, can precipitate the embolic event.
Show evidence (1 reference)
PMID:14970983 SUPPORT Human Clinical
"An increased intradiskal pressure resulting from axial loading of the vertebral column with a concomitant Valsalva maneuver is thought to be the initiating event for the embolus."
This supports axial loading with Valsalva as a precipitating physical context.
{ }

Source YAML

click to show
name: Fibrocartilaginous Embolism
creation_date: "2026-05-05T11:41:54Z"
updated_date: "2026-05-05T11:41:54Z"
description: >-
  Fibrocartilaginous embolism is a rare vascular cause of spinal cord
  infarction in which nucleus pulposus or intervertebral disc fibrocartilage
  embolizes to spinal vessels, often after axial loading, exertion, or minor
  trauma. The resulting central or spinal arterial occlusion produces acute
  ischemic myelopathy with sudden back or neck pain, weakness or paralysis, and
  sensory or autonomic deficits.
category: Complex
disease_term:
  preferred_term: fibrocartilaginous embolism
  term:
    id: MONDO:0023152
    label: fibrocartilaginous embolism
parents:
- Vascular disorder
synonyms:
- Fibrocartilaginous embolic myelopathy
pathophysiology:
- name: Pressure-related intervertebral disc injury
  description: >-
    Axial loading, Valsalva-like maneuvers, or related pressure events can
    acutely increase intradiscal pressure and initiate nucleus pulposus
    displacement.
  locations:
  - preferred_term: intervertebral disk
    term:
      id: UBERON:0001066
      label: intervertebral disk
  downstream:
  - target: Nucleus pulposus fibrocartilage embolization
    description: Pressure-related disc injury can introduce nucleus pulposus material into spinal vasculature.
  evidence:
  - reference: PMID:14970983
    reference_title: "Fibrocartilaginous embolism--an uncommon cause of spinal cord infarction: a case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An increased intradiskal pressure resulting from axial loading of the vertebral column with a concomitant Valsalva maneuver is thought to be the initiating event for the embolus.
    explanation: This supports axial loading and Valsalva-related intradiscal pressure as the initiating event.
- name: Nucleus pulposus fibrocartilage embolization
  description: >-
    Acute vertical disc herniation can introduce nucleus pulposus
    fibrocartilage into spinal vasculature, with retrograde embolization to a
    central or spinal artery.
  locations:
  - preferred_term: intervertebral disk
    term:
      id: UBERON:0001066
      label: intervertebral disk
  - preferred_term: anterior spinal artery
    term:
      id: UBERON:0005431
      label: anterior spinal artery
  downstream:
  - target: Spinal cord infarction
    description: Fibrocartilaginous embolic occlusion obstructs spinal cord blood flow and causes ischemic infarction.
  evidence:
  - reference: PMID:14970983
    reference_title: "Fibrocartilaginous embolism--an uncommon cause of spinal cord infarction: a case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is postulated that an acute vertical disk herniation of the nucleus pulposus material can lead to spinal cord infarction by a retrograde embolization to the central artery.
    explanation: This review/case report states the proposed nucleus pulposus embolization mechanism.
  - reference: DOI:10.1177/0883073809355822
    reference_title: "Spinal Cord Infarction Due to Fibrocartilaginous Embolization: The Role of Diffusion Weighted Imaging and Short-Tau Inversion Recovery Sequences"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fibrocartilaginous embolization is a rare cause of ischemic myelopathy caused by embolization of intersomatic disk nucleus pulposus into spinal vasculature during Valsalva-like maneuvers.
    explanation: This independently supports nucleus pulposus embolization into spinal vasculature.
- name: Spinal cord infarction
  description: >-
    Vascular occlusion by fibrocartilage causes spinal cord ischemia and
    infarction, which can present as acute myelopathy and may be misdiagnosed as
    inflammatory transverse myelitis.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  biological_processes:
  - preferred_term: response to hypoxia
    modifier: INCREASED
    term:
      id: GO:0001666
      label: response to hypoxia
  downstream:
  - target: Acute ischemic myelopathy
    description: Spinal cord infarction injures motor, sensory, and autonomic tracts, producing abrupt myelopathic deficits.
  evidence:
  - reference: PMID:26833287
    reference_title: "Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fibrocartilaginous Embolism (FCE) has been reported to represent 5.5% of spinal cord infarctions.
    explanation: This review identifies FCE as a cause of spinal cord infarction.
  - reference: PMID:26833287
    reference_title: "Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      FCE of the spinal cord, often mis-diagnosed as transverse myelitis, may be more common than presumed.
    explanation: This supports spinal-cord FCE as an acute myelopathy mimic.
- name: Acute ischemic myelopathy
  description: >-
    Infarction of the spinal cord causes abrupt motor and sensory dysfunction,
    often with severe back pain at onset and variable long-term neurological
    recovery.
  locations:
  - preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  evidence:
  - reference: PMID:37873837
    reference_title: "Acute Presentation and Long-Term Rehabilitation Follow-Up of Ischemic Myelopathy Due to Clinically Suspected Fibrocartilaginous Embolism in an Adolescent Male: A Case Report and Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present the case of an otherwise healthy 17-year-old student who experienced sudden onset of severe low-back pain amidst intensive physical training, which rapidly deteriorated to complete sensory-motor paralysis of his lower limbs.
    explanation: This case/review supports sudden pain followed by severe sensory-motor myelopathy.
phenotypes:
- category: Neurological
  name: Spinal cord infarction
  diagnostic: true
  description: Spinal cord infarction is the defining vascular injury caused by fibrocartilaginous embolization.
  phenotype_term:
    preferred_term: Spinal cord infarction
  evidence:
  - reference: PMID:26833287
    reference_title: "Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fibrocartilaginous Embolism (FCE) has been reported to represent 5.5% of spinal cord infarctions.
    explanation: This supports spinal cord infarction as the core FCE lesion.
- category: Neurological
  name: Acute myelopathy
  diagnostic: true
  description: Acute spinal cord dysfunction is the defining clinical presentation.
  phenotype_term:
    preferred_term: Acute myelopathy
  evidence:
  - reference: PMID:26833287
    reference_title: "Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      FCE of the spinal cord, often mis-diagnosed as transverse myelitis, may be more common than presumed.
    explanation: This supports acute myelopathy as the clinical syndrome frequently confused with transverse myelitis.
- category: Musculoskeletal
  name: Back pain
  description: Sudden severe back pain can occur near onset.
  phenotype_term:
    preferred_term: Back pain
    term:
      id: HP:0003418
      label: Back pain
    temporality: ACUTE
  evidence:
  - reference: PMID:37873837
    reference_title: "Acute Presentation and Long-Term Rehabilitation Follow-Up of Ischemic Myelopathy Due to Clinically Suspected Fibrocartilaginous Embolism in an Adolescent Male: A Case Report and Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present the case of an otherwise healthy 17-year-old student who experienced sudden onset of severe low-back pain amidst intensive physical training, which rapidly deteriorated to complete sensory-motor paralysis of his lower limbs.
    explanation: This directly supports sudden severe low-back pain at presentation.
- category: Neurological
  name: Lower-limb paralysis
  description: Spinal cord infarction can cause acute lower-limb motor paralysis.
  phenotype_term:
    preferred_term: Paraplegia
    term:
      id: HP:0010550
      label: Paraplegia
  evidence:
  - reference: PMID:37873837
    reference_title: "Acute Presentation and Long-Term Rehabilitation Follow-Up of Ischemic Myelopathy Due to Clinically Suspected Fibrocartilaginous Embolism in an Adolescent Male: A Case Report and Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present the case of an otherwise healthy 17-year-old student who experienced sudden onset of severe low-back pain amidst intensive physical training, which rapidly deteriorated to complete sensory-motor paralysis of his lower limbs.
    explanation: This supports acute lower-limb sensory-motor paralysis.
- category: Neurological
  name: Paraparesis
  description: Progressive paraparesis can occur after exertion or axial loading.
  phenotype_term:
    preferred_term: Paraparesis
    term:
      id: HP:0002385
      label: Paraparesis
  evidence:
  - reference: PMID:14970983
    reference_title: "Fibrocartilaginous embolism--an uncommon cause of spinal cord infarction: a case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present a previously healthy 16-year-old boy with sudden onset of back pain and progressive paraparesis within 36 hours after lifting exercises in a squat position.
    explanation: This case/review supports progressive paraparesis after exertion.
- category: Neurological
  name: Somatic sensory dysfunction
  description: Acute spinal cord infarction can cause sensory deficits alongside motor paralysis.
  phenotype_term:
    preferred_term: Somatic sensory dysfunction
    term:
      id: HP:0003474
      label: Somatic sensory dysfunction
  evidence:
  - reference: PMID:37873837
    reference_title: "Acute Presentation and Long-Term Rehabilitation Follow-Up of Ischemic Myelopathy Due to Clinically Suspected Fibrocartilaginous Embolism in an Adolescent Male: A Case Report and Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      complete sensory-motor paralysis of his lower limbs.
    explanation: This directly supports sensory dysfunction as part of FCE-associated lower-limb sensory-motor paralysis.
- category: Genitourinary
  name: Autonomic bladder or bowel dysfunction
  description: Anterior spinal artery territory ischemia can injure lateral horn autonomic pathways, producing bowel or bladder dysfunction.
  phenotype_term:
    preferred_term: Urinary incontinence
    term:
      id: HP:0000020
      label: Urinary incontinence
  evidence:
  - reference: PMID:37456462
    reference_title: Incomplete Anterior Spinal Artery Syndrome Responsive to Intrathecal Baclofen.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      fecal or urinary incontinence
    explanation: This supports autonomic bladder or bowel dysfunction in anterior spinal artery ischemia, a downstream spinal cord infarction pattern relevant to FCE.
environmental:
- name: Axial loading or Valsalva-associated spinal pressure
  description: >-
    Activities that increase intradiscal pressure, such as axial loading with a
    Valsalva maneuver or lifting exercises, can precipitate the embolic event.
  presence: Positive
  evidence:
  - reference: PMID:14970983
    reference_title: "Fibrocartilaginous embolism--an uncommon cause of spinal cord infarction: a case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An increased intradiskal pressure resulting from axial loading of the vertebral column with a concomitant Valsalva maneuver is thought to be the initiating event for the embolus.
    explanation: This supports axial loading with Valsalva as a precipitating physical context.
diagnosis:
- name: Clinico-radiologic diagnosis with exclusion of inflammatory mimics
  description: >-
    Diagnosis is usually clinical and radiologic because tissue confirmation is
    uncommon; work-up excludes infectious, autoimmune, inflammatory, and
    neoplastic causes and correlates the presentation with spinal cord
    infarction.
  results: >-
    Sudden myelopathy with spinal cord infarction, plausible disc or exertional
    trigger, and no better inflammatory, infectious, autoimmune, or neoplastic
    explanation supports suspected FCE.
  evidence:
  - reference: PMID:14970983
    reference_title: "Fibrocartilaginous embolism--an uncommon cause of spinal cord infarction: a case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Laboratory investigation showed no evidence of infectious, autoimmune, inflammatory, or neoplastic causes.
    explanation: This supports exclusion of alternative causes in suspected FCE diagnosis.
  - reference: PMID:26833287
    reference_title: "Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The 41 tissue proven cases are summarized and a schematic approach to the clinical diagnosis of FCE, deducted from their clinical findings, is presented.
    explanation: This supports a clinical diagnostic approach when histologic confirmation is unavailable.
- name: MRI-supported spinal cord infarction diagnosis
  description: >-
    MRI supports suspected fibrocartilaginous embolism by showing spinal cord
    lesions consistent with infarction, including T2 hyperintensity and
    diffusion-weighted evidence of cytotoxic edema.
  results: >-
    T2-hyperintense spinal cord lesions and diffusion-weighted imaging evidence
    of ischemia support FCE when clinical history and exclusion work-up are
    compatible.
  evidence:
  - reference: DOI:10.1177/0883073809355822
    reference_title: "Spinal Cord Infarction Due to Fibrocartilaginous Embolization: The Role of Diffusion Weighted Imaging and Short-Tau Inversion Recovery Sequences"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnostic criteria are based on patient’s clinical history, magnetic resonance evidence of T2-hyperintense spinal cord lesion, and exclusion of other causes of ischemic myelopathy.
    explanation: This supports MRI-based diagnosis with exclusion of other ischemic myelopathy causes.
  - reference: DOI:10.1177/0883073809355822
    reference_title: "Spinal Cord Infarction Due to Fibrocartilaginous Embolization: The Role of Diffusion Weighted Imaging and Short-Tau Inversion Recovery Sequences"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      diffusion-weighted imaging sequences played a pivotal role showing the ischemic nature of spinal cord lesions.
    explanation: This supports diffusion-weighted imaging as a useful MRI sequence for ischemic spinal cord lesions in FCE.
treatments:
- name: Supportive rehabilitation after ischemic myelopathy
  description: >-
    Treatment is mainly supportive, focused on acute assessment, prevention of
    complications, and inpatient or outpatient rehabilitation to maximize
    neurologic and functional recovery.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:37873837
    reference_title: "Acute Presentation and Long-Term Rehabilitation Follow-Up of Ischemic Myelopathy Due to Clinically Suspected Fibrocartilaginous Embolism in an Adolescent Male: A Case Report and Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He subsequently received inpatient rehabilitation treatment for four months, after which he was followed as an outpatient for a total period of 16 months.
    explanation: This supports rehabilitation-centered management after suspected FCE ischemic myelopathy.
- name: IV methylprednisolone during initial infarction work-up
  description: >-
    IV methylprednisolone has been used during initial evaluation when the
    differential includes inflammatory myelopathy, but this is case-level
    management rather than proven disease-specific therapy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: methylprednisolone
      term:
        id: NCIT:C647
        label: Methylprednisolone
  evidence:
  - reference: PMID:37873837
    reference_title: "Acute Presentation and Long-Term Rehabilitation Follow-Up of Ischemic Myelopathy Due to Clinically Suspected Fibrocartilaginous Embolism in an Adolescent Male: A Case Report and Review."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He was treated with IV Methylprednisolone and anticoagulation after the initial work-up suggested spinal cord infarction.
    explanation: This supports reported use of IV methylprednisolone during initial suspected spinal cord infarction work-up.
- name: Anticoagulation during initial infarction work-up
  description: >-
    Anticoagulation has been used during initial management of suspected spinal
    cord infarction in FCE, but evidence remains anecdotal and not
    disease-specific.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: anticoagulant agent
      term:
        id: NCIT:C263
        label: Anticoagulant Agent
  evidence:
  - reference: PMID:37873837
    reference_title: "Acute Presentation and Long-Term Rehabilitation Follow-Up of Ischemic Myelopathy Due to Clinically Suspected Fibrocartilaginous Embolism in an Adolescent Male: A Case Report and Review."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He was treated with IV Methylprednisolone and anticoagulation after the initial work-up suggested spinal cord infarction.
    explanation: This supports reported anticoagulation during initial suspected spinal cord infarction work-up.
📚

References & Deep Research

Deep Research

1
Falcon
1. Disease Information
Edison Scientific Literature 49 citations 2026-05-05T08:13:33.034613

1. Disease Information

1.1 Concise overview / definition

Fibrocartilaginous embolism (FCE) is an ischemic myelopathy (spinal cord infarction) caused by embolization of fibrocartilaginous material, presumed to originate from the nucleus pulposus of the intervertebral disc, into vessels supplying the spinal cord. In clinical practice it is typically a diagnosis of exclusion because definitive confirmation is usually postmortem or via biopsy/histopathology. (cuello2014acutecervicalmyelopathy pages 1-2, taous2023spinalcordinfarction pages 1-2, abdelrazek2016fibrocartilaginousembolisma pages 5-6)

1.2 Synonyms / alternative names

  • Fibrocartilaginous embolization (human literature) (manara2010spinalcordinfarction pages 1-3, abdelrazek2016fibrocartilaginousembolisma pages 1-2)
  • Fibrocartilaginous embolic myelopathy (FCEM) (common in veterinary literature; used as a close naturally occurring analog) (risio2010fibrocartilaginousembolicmyelopathy pages 6-8)

1.3 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

Within the retrieved full-text evidence, explicit ontology identifiers (OMIM, Orphanet, ICD-10/ICD-11, MeSH, MONDO) were not stated. Therefore, this report cannot provide validated identifier mappings from the present evidence set. (cuello2014acutecervicalmyelopathy pages 1-2, abdelrazek2016fibrocartilaginousembolisma pages 5-6)

1.4 Evidence source type

Evidence is primarily: - Human clinical: case reports, systematic reviews, and SCI cohorts with FCE as a subgroup (cuello2014acutecervicalmyelopathy pages 1-2, castello2023spinalcordinfarction pages 1-2, mateen2011clinicallysuspectedfibrocartilaginous pages 6-7) - Veterinary clinical/pathology: naturally occurring FCEM in dogs/cats with histologic confirmation and MRI phenotype (risio2010fibrocartilaginousembolicmyelopathy pages 6-8, togawa2024outcomeinparaplegic pages 1-2) - Clinical registry/trial record: observational SCI cohort explicitly including FCE criteria (NCT04372758 chunk 1)


2. Etiology

2.1 Primary causal factors

Mechanistic cause (current understanding): migration/embolization of nucleus pulposus–derived fibrocartilaginous material into spinal cord vasculature causing arterial occlusion and infarction. (taous2023spinalcordinfarction pages 1-2, abdelrazek2016fibrocartilaginousembolisma pages 5-6, abdelrazek2016fibrocartilaginousembolisma pages 1-2)

2.2 Risk factors

FCE often follows minor trauma or mechanical/pressure events that plausibly increase intradiscal or intra-vertebral pressure (e.g., heavy lifting, physical exertion, bending, Valsalva-like maneuvers). (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, zalewski2019characteristicsofspontaneous pages 3-4, abdelrazek2016fibrocartilaginousembolisma pages 5-6)

Quantitative examples: - In a Mayo clinically suspected FCE cohort, 7/9 (78%) had a precipitating event within 24 hours (motor vehicle accident, heavy lifting, exertion, bending). (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3) - In spontaneous SCI more broadly, 33/133 (25%) reported a precipitating physical maneuver (e.g., lifting/Valsalva). (zalewski2019characteristicsofspontaneous pages 3-4)

Vascular risk factors: Many patients with spontaneous SCI have vascular risk factors, but FCE is considered particularly in patients with fewer traditional vascular risk factors and supportive disc/vertebral imaging changes; some proposed criteria exclude patients with >2 vascular risk factors. (mateen2011clinicallysuspectedfibrocartilaginous pages 7-8, zalewski2019characteristicsofspontaneous pages 1-2)

2.3 Protective factors

No protective genetic or environmental factors were identified in the retrieved evidence. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7, abdelrazek2016fibrocartilaginousembolisma pages 5-6)

2.4 Gene–environment interactions

No validated gene–environment interactions were identified for human FCE in the retrieved evidence. (abdelrazek2016fibrocartilaginousembolisma pages 5-6)


3. Phenotypes (clinical presentation)

3.1 Core phenotype spectrum

Typical presentation involves: - Acute back/neck pain followed by rapid neurological deficit (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, cuello2014acutecervicalmyelopathy pages 1-2) - Acute paresis/paralysis (paraparesis/paraplegia or quadriparesis/quadriplegia), often initially flaccid with hyporeflexia (alfarsi2023spinalcordinfarct pages 2-4, chukwudelunzu2025fibrocartilaginousembolismspinala pages 2-3) - Sensory level; commonly selective impairment of pain/temperature (spinothalamic) with relative dorsal column sparing in anterior spinal artery territory presentations (alfarsi2023spinalcordinfarct pages 2-4, zalewski2019characteristicsofspontaneous pages 3-4) - Autonomic dysfunction (neurogenic bladder/bowel) (alfarsi2023spinalcordinfarct pages 2-4)

3.2 Age of onset and temporal profile

  • FCE is described across ages; reported human cases include adolescents and middle-aged adults (alfarsi2023spinalcordinfarct pages 2-4, cuello2014acutecervicalmyelopathy pages 1-2)
  • Time course is often hyperacute-to-acute.
  • In the Mayo suspected-FCE cohort: time to maximal weakness ≤4 h in 8/9 and <12 h in all (range minutes to 11 h). (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3)
  • In spontaneous SCI cohort (not limited to FCE): nadir within 12 h in 77%. (zalewski2019characteristicsofspontaneous pages 1-2)

3.3 Severity/progression

Deficits typically progress over minutes to hours to a nadir and then stabilize; severe disability is common, but recovery varies depending on lesion extent and level and access to rehabilitation. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7, shah2018fibrocartilaginousemboliin pages 4-4)

3.4 Suggested HPO terms (non-exhaustive)

Based on the above clinical features: - Acute pain: Back pain (HP:0003418); Neck pain (HP:0000467) - Motor deficits: Paraplegia (HP:0003401); Quadriplegia (HP:0003293); Muscle weakness (HP:0001324) - Sensory deficits: Loss of pain sensation (HP:0007012); Sensory level (HP:0033725) (term availability may vary across HPO releases) - Autonomic: Neurogenic bladder (HP:0000010); Urinary retention (HP:0000016)

(These HPO suggestions are ontology-mapping aids; the retrieved papers describe the phenotypes but do not provide HPO codes.) (alfarsi2023spinalcordinfarct pages 2-4, mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, zalewski2019characteristicsofspontaneous pages 3-4)


4. Genetic / Molecular Information

4.1 Causal genes / variants

No causal genes, pathogenic germline variants, or inherited pattern are supported by the retrieved evidence. Human FCE is primarily treated as a mechanical/vascular phenomenon rather than a monogenic disease. (abdelrazek2016fibrocartilaginousembolisma pages 5-6)

4.2 Molecular profiling / omics

No transcriptomic/proteomic/metabolomic signatures specific to human FCE were identified in the retrieved evidence. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7)


5. Environmental Information

5.1 Environmental/lifestyle triggers

The most consistently reported environmental/behavioral correlates are activities increasing spinal load/pressure, including heavy lifting and physical exertion, and other minor traumatic or Valsalva-like events. (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, zalewski2019characteristicsofspontaneous pages 3-4)

5.2 Infectious agents

No infectious etiology is supported; infectious/inflammatory causes are part of the differential diagnosis to be excluded. (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, abdelrazek2016fibrocartilaginousembolisma pages 5-6)


6. Mechanism / Pathophysiology

6.1 Causal chain (trigger → lesion → symptoms)

  1. Trigger (often minor exertion/trauma/pressure event) temporally associated with symptom onset (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, abdelrazek2016fibrocartilaginousembolisma pages 5-6)
  2. Disc-derived fibrocartilage enters vasculature (nucleus pulposus material migration/embolization) (taous2023spinalcordinfarction pages 1-2, abdelrazek2016fibrocartilaginousembolisma pages 1-2)
  3. Vascular occlusion (often radicular/anterior spinal artery territory) → spinal cord ischemia and infarction (manara2010spinalcordinfarction pages 3-4, cuello2014acutecervicalmyelopathy pages 1-2)
  4. Clinical syndrome of acute myelopathy: pain, rapid paralysis/weakness, sensory level, autonomic dysfunction (alfarsi2023spinalcordinfarct pages 2-4, mateen2011clinicallysuspectedfibrocartilaginous pages 2-3)

6.2 Upstream vs downstream processes

  • Upstream: mechanical/disc event leading to embolization (taous2023spinalcordinfarction pages 1-2, abdelrazek2016fibrocartilaginousembolisma pages 5-6)
  • Downstream: ischemic cytotoxic edema and infarction, which is detectable by diffusion restriction on MRI and leads to neurologic deficit (manara2010spinalcordinfarction pages 3-4, zalewski2019characteristicsofspontaneous pages 3-4)

6.3 Suggested GO biological process terms (conceptual mapping)

  • Ischemic process / response to hypoxia (e.g., “response to hypoxia”, “cell death”) consistent with infarction biology (supported indirectly via DWI evidence of cytotoxic edema rather than specific molecular assays). (manara2010spinalcordinfarction pages 3-4)

6.4 Suggested Cell Ontology (CL) cell types

Primary tissue affected is spinal cord gray/white matter; cell types implicated in ischemic injury include: - Spinal cord neuron populations (especially anterior horn motor neurons in ASA territory) (manara2010spinalcordinfarction pages 3-4) - Glial cells involved in infarct evolution (inferred from ischemic myelopathy context; not directly profiled here). (manara2010spinalcordinfarction pages 3-4)


7. Anatomical Structures Affected

7.1 Organ/system level

  • Primary: spinal cord (central nervous system). (cuello2014acutecervicalmyelopathy pages 1-2, abdelrazek2016fibrocartilaginousembolisma pages 1-2)

7.2 Localization patterns

  • Human systematic review: cervical cord frequently involved (48% in one review) (cuello2014acutecervicalmyelopathy pages 1-2)
  • In a 2023 SCI cohort: thoracic region most often affected overall (68.2%) (not FCE-specific) (castello2023spinalcordinfarction pages 1-2)

7.3 Suggested UBERON terms (conceptual mapping)

  • Spinal cord (UBERON:0002240)
  • Segmental localization (cervical/thoracic/lumbar spinal cord)

8. Temporal Development

8.1 Onset

Hyperacute/acute onset is characteristic. - Mayo suspected-FCE cohort: maximal deficits within <12 h in all cases (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3) - Spontaneous SCI cohort: nadir within 12 h in 77% (zalewski2019characteristicsofspontaneous pages 1-2)

8.2 Course

Often stabilizes after reaching nadir; longer-term course depends on infarct size/level and rehabilitation. (shah2018fibrocartilaginousemboliin pages 4-4)


9. Inheritance and Population

9.1 Epidemiology

Population incidence/prevalence for human FCE remains poorly defined; however, proportions within SCI cohorts are reported: - Mayo SCI cohort: 9/164 (5.5%; 95% CI 2.5–10.2%) clinically suspected FCE among acute spinal cord infarctions. (mateen2011clinicallysuspectedfibrocartilaginous pages 1-2) - 2023 single-center 41-patient SCI series: fibrocartilaginous embolism 14.6% (6 cases); etiology undetermined 29.3%. (castello2023spinalcordinfarction pages 1-2, castello2023spinalcordinfarction pages 5-7)

9.2 Sex and age distribution

  • Systematic review of reported FCE cases: median age 37 years; 56% female. (cuello2014acutecervicalmyelopathy pages 1-2)
  • Mayo suspected-FCE cohort: 6 men and 3 women (median age 46). (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3)

10. Diagnostics

10.1 Key clinical/imaging tests

MRI spine (core test): - T2 patterns typical for SCI include “owl eyes” and “pencil-like” hyperintensity (SCI data; also leveraged in FCE suspicion). (zalewski2019characteristicsofspontaneous pages 3-4, zalewski2019characteristicsofspontaneous pages 1-2) - FCE case reports emphasize cord swelling and T2 hyperintensity, often without early enhancement; adjacent disc pathology or Schmorl nodes can support FCE mechanism. (yamaguchi2019fibrocartilaginousembolismof pages 5-8, alfarsi2023spinalcordinfarct pages 2-4)

Diffusion-weighted imaging (DWI/ADC): - Helps distinguish cytotoxic (ischemic) from vasogenic (inflammatory) edema; recommended for acute myelopathy workups. (manara2010spinalcordinfarction pages 3-4, manara2010spinalcordinfarction pages 4-5) - In spontaneous SCI cohort: DWI/ADC restriction in 19/29 (67%). (zalewski2019characteristicsofspontaneous pages 3-4)

CSF: usually normal or mild nonspecific abnormalities; used to exclude inflammation. - In spontaneous SCI: mild inflammation in 7/89 (8%) (elevated nucleated cells). (zalewski2019characteristicsofspontaneous pages 1-2)

10.2 Proposed diagnostic criteria / algorithms (expert consensus-level)

  • Spontaneous SCI diagnostic criteria were proposed and validated in a large JAMA Neurology cohort; hallmark clinical discriminator includes rapid time-to-nadir (<12 h typical) with supportive MRI patterns and confirmatory DWI/vertebral infarction findings. (zalewski2019characteristicsofspontaneous pages 1-2, zalewski2019characteristicsofspontaneous pages 3-4)
  • FCE-focused stepwise approach (review-based): establish myelopathy; exclude trauma/compression by imaging; exclude inflammatory myelopathies using CSF (no pleocytosis/IgG index elevation) and lack of gadolinium enhancement; interpret vascular distribution and supportive adjacent disc/vertebral findings as increasing likelihood. (abdelrazek2016fibrocartilaginousembolisma pages 5-6, chukwudelunzu2025fibrocartilaginousembolismspinala pages 2-3)

10.3 Differential diagnosis

Frequently confounded with inflammatory myelopathies (e.g., transverse myelitis) and other acute myelopathies; multiple reports note misdiagnosis risk and delay. (alfarsi2023spinalcordinfarct pages 2-4, zalewski2019characteristicsofspontaneous pages 1-2)

10.4 Pathology

Definitive diagnosis is histopathologic identification of fibrocartilaginous material within spinal cord vessels (often autopsy). (risio2010fibrocartilaginousembolicmyelopathy pages 6-8, abdelrazek2016fibrocartilaginousembolisma pages 1-2)


11. Outcome / Prognosis

11.1 Human prognosis

  • In Mayo clinically suspected FCE series: median mRS 4 (range 3–5) and Barthel index median 45 among 7, reflecting substantial disability; no deaths or recurrences at mean 2.90-year follow-up. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7)
  • In a 2023 SCI cohort (all-cause SCI, not FCE-specific): after median 24 months, 29.2% walked unaided; 3-month mortality 9.8% and mortality at end of follow-up 36.6%. (castello2023spinalcordinfarction pages 5-7)

11.2 Prognostic factors (general SCI / FCE-inferred)

Severity at onset and lesion extent influence recovery; SCI literature identifies older age, vascular risk factors, and anterior spinal artery watershed involvement as worse prognostic indicators. (mcbride2024nonsurgicalspinalcord pages 3-4)


12. Treatment

12.1 Pharmacotherapy and acute interventions

Evidence does not support a specific proven acute therapy for FCE. - In Mayo suspected-FCE series, IV steroids, plasma exchange, IV heparin, IVIG, and decompressive surgery did not yield meaningful acute improvement. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7) - Some cases are treated with antiplatelet therapy (e.g., aspirin) after excluding inflammatory etiologies; this is largely extrapolated rather than evidence-based for FCE specifically. (alfarsi2023spinalcordinfarct pages 2-4, castello2023spinalcordinfarction pages 5-7)

12.2 Neurocritical care / neuroprotection (case-based)

A pediatric illustrative case applied continuous CSF drainage plus mean arterial pressure augmentation (permissive hypertension) and steroids with substantial neurological improvement; this is hypothesis-generating and extrapolated from aortic surgery spinal cord protection principles. (fedaravicius2021successfulmanagementof pages 1-2)

12.3 Rehabilitation (real-world implementation)

Rehabilitation is consistently emphasized. - Pediatric rehabilitation case literature reports substantial functional gains after intensive inpatient rehabilitation and advocates early initiation of comprehensive rehab. (shah2018fibrocartilaginousemboliin pages 4-4) - In an inpatient rehab cohort of probable FCEM (31 patients), functional scores improved (motor FIM increased from 36 to 69 during rehab), though many still used wheelchairs as primary mobility at discharge. (moore2018fibrocartilaginousembolicmyelopathy pages 1-2)

12.4 MAXO term suggestions (conceptual mapping)

  • Rehabilitation therapy (e.g., physical therapy/occupational therapy) (shah2018fibrocartilaginousemboliin pages 4-4)
  • Antiplatelet therapy (aspirin in some cases) (alfarsi2023spinalcordinfarct pages 2-4)
  • Cerebrospinal fluid drainage (case-based neuroprotection) (fedaravicius2021successfulmanagementof pages 1-2)
  • Blood pressure augmentation / hemodynamic support (fedaravicius2021successfulmanagementof pages 1-2)

13. Prevention

No validated primary prevention strategy exists because FCE is rare, unpredictable, and typically associated with nonspecific mechanical triggers. Practical prevention is therefore limited to general spine safety and vascular-risk management when appropriate, but this is not evidence-based for FCE prevention specifically in the retrieved literature. (abdelrazek2016fibrocartilaginousembolisma pages 5-6)


14. Other Species / Natural Disease

14.1 Naturally occurring veterinary analogs

In veterinary neurology, fibrocartilaginous embolic myelopathy (FCEM) is a well-recognized cause of peracute noncompressive myelopathy in dogs/cats, with diagnosis definitively confirmed by histology showing fibrocartilaginous material in spinal vessels. (risio2010fibrocartilaginousembolicmyelopathy pages 6-8)

14.2 Veterinary outcome statistics (useful for comparative prognosis biology)

In a 2024 cohort of paraplegic dogs with thoracolumbar FCEM/ANNPE: - Deep pain positive: 9/14 (64.3%) regained independent ambulation - Deep pain negative: 1/12 (8.3%) regained independent ambulation - Deep pain negative status strongly predicted poor recovery (OR 47.40). (togawa2024outcomeinparaplegic pages 1-2)

These naturally occurring datasets support the central prognostic role of initial neurologic severity and can inform translational hypotheses, but they are not direct human clinical evidence. (togawa2024outcomeinparaplegic pages 1-2, risio2010fibrocartilaginousembolicmyelopathy pages 6-8)


15. Model Organisms

No engineered genetic model organism systems were identified in the retrieved evidence. The most relevant “models” are naturally occurring veterinary FCEM cases and imaging/clinical cohorts, which provide translationally relevant ischemic myelopathy phenotypes and opportunities for biomarker and neuroprotection research. (risio2010fibrocartilaginousembolicmyelopathy pages 6-8, togawa2024outcomeinparaplegic pages 1-2)


Recent developments and latest research emphasis (2023–2024)

  • Human cohort-level update (2023): a 41-patient spinal cord infarction series reported fibrocartilaginous embolism as 14.6% of etiologies and documented major long-term disability (only 29.2% walking unaided at median 24 months) and substantial mortality, underscoring persistent unmet needs in diagnosis and post-acute care. (castello2023spinalcordinfarction pages 1-2, castello2023spinalcordinfarction pages 5-7)
  • Prognosis synthesis (2024): a long-term follow-up case series/review context emphasizes that a large fraction of SCI remains of unclear etiology in published studies (24–74%) and that long-term disability is common, with prognosis linked to initial severity and risk factors. (mcbride2024nonsurgicalspinalcord pages 3-4)
  • Veterinary prognosis (2024): robust prognostic discrimination using deep pain sensation in severe FCEM/ANNPE provides an example of clinically actionable predictors in a natural disease analog. (togawa2024outcomeinparaplegic pages 1-2)

Clinical trials / registries

  • ClinicalTrials.gov NCT04372758 (EDMIAS): completed retrospective observational cohort (n=60) aimed at characterizing acute spontaneous SCI (2010–2020) and explicitly includes evaluation/application of fibrocartilaginous embolism criteria (2015) as a secondary outcome, reflecting ongoing efforts to operationalize FCE diagnosis within SCI research frameworks. URL: https://clinicaltrials.gov/study/NCT04372758 (NCT04372758 chunk 1)

Key limitations / data gaps

  • Ontology identifier mappings (MONDO/MeSH/ICD/Orphanet) were not available in retrieved evidence texts.
  • Human FCE evidence remains dominated by case reports and small series; many treatment strategies are extrapolated from SCI or neuroprotection principles rather than validated by controlled studies. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7, fedaravicius2021successfulmanagementof pages 1-2)

References

  1. (cuello2014acutecervicalmyelopathy pages 1-2): Juan P. Cuello, Santiago Ortega-Gutierrez, Guillermo Linares, Sachin Agarwal, Alyson Cunningham, Jay P. Mohr, Stephan A. Mayer, Randolph S. Marshall, Jan Claassen, Neeraj Badjatia, Mitchel S.V. Elkind, and Kiwon Lee. Acute cervical myelopathy due to presumed fibrocartilaginous embolism: a case report and systematic review of the literature. Journal of Spinal Disorders and Techniques, 27:E276–E281, Dec 2014. URL: https://doi.org/10.1097/bsd.0000000000000115, doi:10.1097/bsd.0000000000000115. This article has 18 citations.

  2. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7): F. Mateen, F. Mateen, Priya Monrad, A. L. Hunderfund, Carrie E. Robertson, and E. J. Sorenson. Clinically suspected fibrocartilaginous embolism: clinical characteristics, treatments, and outcomes. European Journal of Neurology, 18:218-225, Feb 2011. URL: https://doi.org/10.1111/j.1468-1331.2010.03200.x, doi:10.1111/j.1468-1331.2010.03200.x. This article has 93 citations and is from a domain leading peer-reviewed journal.

  3. (abdelrazek2016fibrocartilaginousembolisma pages 5-6): Mahmoud A. AbdelRazek, Ashkan Mowla, Salman Farooq, Nicholas Silvestri, Robert Sawyer, and Gil Wolfe. Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria. The Journal of Spinal Cord Medicine, 39:146-154, Feb 2016. URL: https://doi.org/10.1080/10790268.2015.1116726, doi:10.1080/10790268.2015.1116726. This article has 116 citations.

  4. (taous2023spinalcordinfarction pages 1-2): Abdellah Taous, Taoufik Boubga, Tarik Boulahri, Soufiane Belabbes, Taoufik Africha, Omar Boulahroud, and Maha Ait Berri. Spinal cord infarction owing to likely fibrocartilaginous embolism. SAS Journal of Medicine, 9:1207-1209, Nov 2023. URL: https://doi.org/10.36347/sasjm.2023.v09i11.015, doi:10.36347/sasjm.2023.v09i11.015. This article has 0 citations.

  5. (alfarsi2023spinalcordinfarct pages 2-4): Said A Al-Farsi, Haifa Al-Abri, Eiman Al-Ajmi, and Abdullah Al-Asmi. Spinal cord infarct due to fibrocartilaginous embolism in an adolescent boy: a case report and literature review. Cureus, Apr 2023. URL: https://doi.org/10.7759/cureus.37319, doi:10.7759/cureus.37319. This article has 7 citations.

  6. (mateen2011clinicallysuspectedfibrocartilaginous pages 1-2): F. Mateen, F. Mateen, Priya Monrad, A. L. Hunderfund, Carrie E. Robertson, and E. J. Sorenson. Clinically suspected fibrocartilaginous embolism: clinical characteristics, treatments, and outcomes. European Journal of Neurology, 18:218-225, Feb 2011. URL: https://doi.org/10.1111/j.1468-1331.2010.03200.x, doi:10.1111/j.1468-1331.2010.03200.x. This article has 93 citations and is from a domain leading peer-reviewed journal.

  7. (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3): F. Mateen, F. Mateen, Priya Monrad, A. L. Hunderfund, Carrie E. Robertson, and E. J. Sorenson. Clinically suspected fibrocartilaginous embolism: clinical characteristics, treatments, and outcomes. European Journal of Neurology, 18:218-225, Feb 2011. URL: https://doi.org/10.1111/j.1468-1331.2010.03200.x, doi:10.1111/j.1468-1331.2010.03200.x. This article has 93 citations and is from a domain leading peer-reviewed journal.

  8. (mateen2011clinicallysuspectedfibrocartilaginous pages 7-8): F. Mateen, F. Mateen, Priya Monrad, A. L. Hunderfund, Carrie E. Robertson, and E. J. Sorenson. Clinically suspected fibrocartilaginous embolism: clinical characteristics, treatments, and outcomes. European Journal of Neurology, 18:218-225, Feb 2011. URL: https://doi.org/10.1111/j.1468-1331.2010.03200.x, doi:10.1111/j.1468-1331.2010.03200.x. This article has 93 citations and is from a domain leading peer-reviewed journal.

  9. (risio2010fibrocartilaginousembolicmyelopathy pages 6-8): Luisa De Risio and Simon R. Platt. Fibrocartilaginous embolic myelopathy in small animals. The Veterinary clinics of North America. Small animal practice, 40 5:859-69, Sep 2010. URL: https://doi.org/10.1016/j.cvsm.2010.05.003, doi:10.1016/j.cvsm.2010.05.003. This article has 121 citations.

  10. (manara2010spinalcordinfarction pages 1-3): Renzo Manara, Milena Calderone, Maria Savina Severino, Valentina Citton, Irene Toldo, Anna Maria Laverda, and Stefano Sartori. Spinal cord infarction due to fibrocartilaginous embolization: the role of diffusion weighted imaging and short-tau inversion recovery sequences. Journal of Child Neurology, 25:1024-1028, Mar 2010. URL: https://doi.org/10.1177/0883073809355822, doi:10.1177/0883073809355822. This article has 34 citations and is from a peer-reviewed journal.

  11. (manara2010spinalcordinfarction pages 3-4): Renzo Manara, Milena Calderone, Maria Savina Severino, Valentina Citton, Irene Toldo, Anna Maria Laverda, and Stefano Sartori. Spinal cord infarction due to fibrocartilaginous embolization: the role of diffusion weighted imaging and short-tau inversion recovery sequences. Journal of Child Neurology, 25:1024-1028, Mar 2010. URL: https://doi.org/10.1177/0883073809355822, doi:10.1177/0883073809355822. This article has 34 citations and is from a peer-reviewed journal.

  12. (yamaguchi2019fibrocartilaginousembolismof pages 5-8): Hiroshi Yamaguchi, Hiroaki Nagase, Masahiro Nishiyama, Shoichi Tokumoto, Daisaku Toyoshima, Yoshinobu Akasaka, Azusa Maruyama, and Kazumoto Iijima. Fibrocartilaginous embolism of the spinal cord in children: a case report and review of literature. Pediatric neurology, 99:3-6, Oct 2019. URL: https://doi.org/10.1016/j.pediatrneurol.2019.04.013, doi:10.1016/j.pediatrneurol.2019.04.013. This article has 29 citations and is from a peer-reviewed journal.

  13. (castello2023spinalcordinfarction pages 1-2): V. Ros Castelló, A. Sánchez Sánchez, E. Natera Villalba, A. Gómez López, P. Parra, F. Rodríguez Jorge, J. Buisán Catevilla, N. García Barragán, J. Masjuán, and Í. Corral. Spinal cord infarction: aetiology, imaging findings, and prognostic factors in a series of 41 patients. Neurología (English Edition), 38:391-398, Jul 2023. URL: https://doi.org/10.1016/j.nrleng.2020.11.004, doi:10.1016/j.nrleng.2020.11.004. This article has 20 citations.

  14. (manara2010spinalcordinfarction pages 4-5): Renzo Manara, Milena Calderone, Maria Savina Severino, Valentina Citton, Irene Toldo, Anna Maria Laverda, and Stefano Sartori. Spinal cord infarction due to fibrocartilaginous embolization: the role of diffusion weighted imaging and short-tau inversion recovery sequences. Journal of Child Neurology, 25:1024-1028, Mar 2010. URL: https://doi.org/10.1177/0883073809355822, doi:10.1177/0883073809355822. This article has 34 citations and is from a peer-reviewed journal.

  15. (castello2023spinalcordinfarction pages 5-7): V. Ros Castelló, A. Sánchez Sánchez, E. Natera Villalba, A. Gómez López, P. Parra, F. Rodríguez Jorge, J. Buisán Catevilla, N. García Barragán, J. Masjuán, and Í. Corral. Spinal cord infarction: aetiology, imaging findings, and prognostic factors in a series of 41 patients. Neurología (English Edition), 38:391-398, Jul 2023. URL: https://doi.org/10.1016/j.nrleng.2020.11.004, doi:10.1016/j.nrleng.2020.11.004. This article has 20 citations.

  16. (mcbride2024nonsurgicalspinalcord pages 3-4): Fionán McBride, Jane Anketell, Gavin V. McDonnell, Suzanne Maguire, and Karen M. Doherty. Non-surgical spinal cord infarction: case series & long-term follow-up of functional outcome. Spinal Cord Series and Cases, Oct 2024. URL: https://doi.org/10.1038/s41394-024-00665-y, doi:10.1038/s41394-024-00665-y. This article has 1 citations and is from a peer-reviewed journal.

  17. (NCT04372758 chunk 1): Descriptive Study of Acute Spontaneous Spinal Cord Infarction. University Hospital, Montpellier. 2020. ClinicalTrials.gov Identifier: NCT04372758

  18. (abdelrazek2016fibrocartilaginousembolisma pages 1-2): Mahmoud A. AbdelRazek, Ashkan Mowla, Salman Farooq, Nicholas Silvestri, Robert Sawyer, and Gil Wolfe. Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria. The Journal of Spinal Cord Medicine, 39:146-154, Feb 2016. URL: https://doi.org/10.1080/10790268.2015.1116726, doi:10.1080/10790268.2015.1116726. This article has 116 citations.

  19. (togawa2024outcomeinparaplegic pages 1-2): Go Togawa, Melissa J. Lewis, and Dillon Devathasan. Outcome in paraplegic dogs with or without pain perception due to thoracolumbar fibrocartilaginous embolic myelopathy or acute non-compressive nucleus pulposus extrusion. Frontiers in Veterinary Science, May 2024. URL: https://doi.org/10.3389/fvets.2024.1406843, doi:10.3389/fvets.2024.1406843. This article has 7 citations and is from a peer-reviewed journal.

  20. (zalewski2019characteristicsofspontaneous pages 3-4): Nicholas L. Zalewski, Alejandro A. Rabinstein, Karl N. Krecke, Robert D. Brown, Eelco F. M. Wijdicks, Brian G. Weinshenker, Timothy J. Kaufmann, Jonathan M. Morris, Allen J. Aksamit, J. D. Bartleson, Giuseppe Lanzino, Melissa M. Blessing, and Eoin P. Flanagan. Characteristics of spontaneous spinal cord infarction and proposed diagnostic criteria. JAMA Neurology, 76:56–63, Jan 2019. URL: https://doi.org/10.1001/jamaneurol.2018.2734, doi:10.1001/jamaneurol.2018.2734. This article has 249 citations and is from a highest quality peer-reviewed journal.

  21. (zalewski2019characteristicsofspontaneous pages 1-2): Nicholas L. Zalewski, Alejandro A. Rabinstein, Karl N. Krecke, Robert D. Brown, Eelco F. M. Wijdicks, Brian G. Weinshenker, Timothy J. Kaufmann, Jonathan M. Morris, Allen J. Aksamit, J. D. Bartleson, Giuseppe Lanzino, Melissa M. Blessing, and Eoin P. Flanagan. Characteristics of spontaneous spinal cord infarction and proposed diagnostic criteria. JAMA Neurology, 76:56–63, Jan 2019. URL: https://doi.org/10.1001/jamaneurol.2018.2734, doi:10.1001/jamaneurol.2018.2734. This article has 249 citations and is from a highest quality peer-reviewed journal.

  22. (chukwudelunzu2025fibrocartilaginousembolismspinala pages 2-3): FE Chukwudelunzu and T Young. Fibrocartilaginous embolism spinal cord infarction, mistaken for glial fibrillary acidic protein autoimmune transverse myelitis: a case report. Unknown journal, 2025.

  23. (shah2018fibrocartilaginousemboliin pages 4-4): Supriya Shah and Phillip Bryant. Fibrocartilaginous emboli in the pediatric population: the role of rehabilitation in facilitating functional recovery. Journal of Pediatric Rehabilitation Medicine, 11:53-56, Mar 2018. URL: https://doi.org/10.3233/prm-170502, doi:10.3233/prm-170502. This article has 11 citations.

  24. (fedaravicius2021successfulmanagementof pages 1-2): Augustinas Fedaravičius, Yael Feinstein, Isaac Lazar, Micky Gidon, Ilan Shelef, Elad Avraham, Arimantas Tamašauskas, and Israel Melamed. Successful management of spinal cord ischemia in a pediatric patient with fibrocartilaginous embolism: illustrative case. Journal of Neurosurgery: Case Lessons, Sep 2021. URL: https://doi.org/10.3171/case21380, doi:10.3171/case21380. This article has 5 citations.

  25. (moore2018fibrocartilaginousembolicmyelopathy pages 1-2): Brittany J. Moore, Anna M. Batterson, Marianne T. Luetmer, and Ronald K. Reeves. Fibrocartilaginous embolic myelopathy: demographics, clinical presentation, and functional outcomes. Spinal Cord, 56:1144-1150, May 2018. URL: https://doi.org/10.1038/s41393-018-0159-y, doi:10.1038/s41393-018-0159-y. This article has 12 citations and is from a peer-reviewed journal.